Edico Genome: Revolutionizing Genome Sequencing Analysis
pharmatechoutlook

Edico Genome: Revolutionizing Genome Sequencing Analysis

CIO VendorGavin Stone, VP of Marketing & Business Development
Today, the genomics industry is placed at an intersection point where it is transitioning from being research and academically focused to providing clinical applications. Industry leaders are re-inventing genomic tools to deliver innovations that are set to turn the global adoption of precision medicine into a reality. Setting a new benchmark by completely revolutionizing genome sequencing analysis, Edico Genome is powering a new era of genomics through its Dynamic Read Analysis for GENomics (DRAGEN) Bio-IT Platform.

“The biggest challenge that the genomics industry is facing today is the high-end analysis costs. Our technology allows users to dramatically lowers their cost of analysis while improving accuracy and speeds,” says Gavin Stone, VP of Marketing and Business Development at Edico Genome. The company’s technology is not only drastically reducing the associated analysis costs, but also improving accuracy— creating the next wave of genomics development.

The DRAGEN Bio-IT Platform supports a wide variety of applications in the genomics space through its end-to-end Genome, Somantic and RNA pipeline solutions, among many others. Developed internally by Edico Genome’s inhouse bioinformatics and engineering team, the solutions capture data coming off of sequencing instruments and inject them into the required algorithms to generate an accurate VCF file in a greatly reducedamount of time, analyzing a whole human genome in just 20 minutes.“We have further developed an additional set of algorithms to raise the level of accuracy that can’t be achieved by the legacy systems or other next-gen solutions,” says Stone.

Edico Genome utilizes a re-configurable processor technology, field-programmable gate arrays (FPGA), through which DRAGEN accelerates its crafted suite of pipelines. FPGAs enable algorithms to be implementedas logic-circuits that can process data extremely efficiently and can also be replicated thousands of times to produce massive parallelism – all while maintaining complete flexibility to change or update the algorithms.

In 2017, we set a GUINNESS WORLD RECORDS™ for fastest analysis of 1,000 Whole Human Genomes simultaneously in two hours and 25 minutes with AWS and the Children’s Hospital of Philadelphia


DRAGEN is available both onsite and in the Cloud, and can also be implemented in a seamless hybrid onsite-Cloud model. The onsite platform leverages an FPGA card installed in a Dell server so that data can be analyzed locally. Recently, with the launch of cloud-based FPGAs, Edico has also been able to make their platform available on the AWS Cloud on their new F1 instances. This has also enabled the firm to collaborate with third party cloud genomic platforms including DNAnexus, Illumina’s BaseSpace Sequence Hub, SevenBridges Genomics as well as being able to make their technology available on the AWS Marketplace.

Founded in early 2013, Edico Genome has grown rapidly, now employing more than 50 full-time team members and serving customers around the globe, across all continents, with the exception of Antarctica. Initially launching with a single pipeline, Edico Genome has since launched many additional pipelines and has continuously improved efficiency, speed, and accuracy across the board.

“This has led us to a point where in 2017, we set a GUINNESS WORLD RECORDS™ for Fastest Analysis of 1,000 Whole Human Genomes, where wesimultaneously analyzed all 1000 genomes in a mere two hours and 25 minutes,” extolsStone. Edico Genome aims to take a further step ahead in bringing advanced accuracy innovationinto its platform by launching DRAGEN V3 in early 2018. Edico is receiving huge traction from the pharma, clinical, and research space and believes that 2018 would be a tremendous year of growth. “The main goal here is to turn precision medicine globally into reality through research enablement and clinical efficiency with our technology,” concludes Stone.